Form 4: Aadi Bioscience Director Caley Castelein Acquires Stock Options

Director Caley Castelein of Aadi Bioscience, Inc. acquired stock options for 45,832 shares on June 12, 2024.

Summary

• Caley Castelein, a director of Aadi Bioscience, Inc., filed a Form 4 to report changes in beneficial ownership.
• On June 12, 2024, Castelein acquired stock options for 45,832 shares of Aadi Bioscience common stock at an exercise price of $1.70.
• The options vest on the earlier of June 12, 2025, or the day before the next annual meeting of stockholders, contingent on Castelein remaining a service provider to the company.
• Following the transaction, Castelein directly owns 45,832 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a common practice and suggests confidence in the company's future, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the stock options is contingent on the director's continued service to the company, aligning their interests with the company's long-term success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially driving long-term value creation.

Key Dates